Baidu
map
CLIN TRANSL ONCOL 润色咨询

Clinical & Translational Oncology

出版年份:2005 年文章数:1541 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:2.2% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2165794, encodeId=4ac12165e9439, content=偏重的研究方向:癌症;临床;预后标志物<br>经验分享:记录一下过程吧。 10.24提交 10.28 reviewer assigned 10.30 under review 希望有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Oct 30 20:47:40 CST 2023, time=2023-10-30, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2102231, encodeId=5f1321022311d, content=偏重的研究方向:乳腺癌;肿瘤<br>经验分享:10.18投稿10.25送外审11.21外审意见回来小修11.22修回11.23接受,效率很快,提出的意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Wed Nov 23 19:49:41 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174151, encodeId=e06f21e41510a, content=审稿速度:1.0<br>经验分享:Nov.3 submission Nov.4 Editor assigned-reviewers assigned Nov.12 日期更新reviewers assigned Nov.14 under review Nov.15 reviewers assigned Nov.30 reviewers assigned Dec.04 reject, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=794c9103199, createdName=ms6000001228150935, createdTime=Sun Dec 10 23:53:27 CST 2023, time=2023-12-10, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2140919, encodeId=690f214091946, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肺癌;基础<br>经验分享:终于结束,就这样!一审审稿比较慢,2个多月,等的有点着急。大修给的截止日期本来是7月份,但因为审稿意见中真正的实验只有一个需要补充,所以修回的比较快,但4个评审意见真是回复到崩溃,太多了。还好四个评审意见都偏积极,我们回复的也够充分,基本都是正面直接回答的。<br>总结:偏临床型杂志,审稿人感觉临床医生居多,所以没有提很多机制性问题,大多问题都跟临床有关。<br><br>14 Feb 2023 submit<br>19 Feb 2023 Editor Invited<br>26 Feb 2023 Under review<br>08 Apr 2023 Reviews Completed<br>12 Apr 2023 Reviews Completed<br>20 Apr 2023 Reviews Completed<br>22 Apr 2023 Major revisions(4个审稿意见,回复意见写了19页)<br>11 May 2023 submit revision R1<br>15 May 2023 Editor Assigned<br>16 May 2023 Major revisions<br>17 May 2023 submit revision R2 又收到了一模一样的大修邮件。沟通后又重新submit <br>18 May 2023 Editor Assigned<br>20 May 2023 Accept<br>26 May 2023 版权协议<br>27 May 2023 proof<br>30 May 2023 online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=631e1736149, createdName=1defbc5bm21(暂无匿称), createdTime=Mon Jun 05 16:54:14 CST 2023, time=2023-06-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2150645, encodeId=eca9215064565, content=偏重的研究方向:肿瘤;癌症;基础<br>经验分享:分享投稿流程 希望可以帮助投稿的小伙伴们 6月7日投稿 6月8日修改参考文献格式重新提交 6月10日分配编辑 6月12日审稿人邀请 审稿人同意 7月21日 小修 审稿人意见很友好 只修改了两处文章标注错误 回答了审稿人两个小问题 7月22日返回修改稿 7月23日接收 审稿时发过两次邮件催稿得到的都是编辑助理回复的文章在审 有消息第一时间通知 编辑处理文章非常快 回复邮件也很快 效率非常高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e178390071, createdName=脸圆环奈, createdTime=Mon Jul 31 16:51:40 CST 2023, time=2023-07-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2145669, encodeId=3f6d2145669f2, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:无理由秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263e1426598, createdName=lichichi1949, createdTime=Fri Jun 30 16:02:30 CST 2023, time=2023-06-30, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2101371, encodeId=6ad721013e159, content=偏重的研究方向:肿瘤<br>经验分享:大佬们under review了一个月昨天又变成Editor Assigned什么意思啊。。这是送了外审没呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Fri Nov 18 18:25:04 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804559, encodeId=f8fc8045597c, content=有没有人一直是reviewers assigned状态啊,这是啥意思啊,而且这个状态还更新了两次日期,这是找不到审稿人是吗?😓, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202406/80984ecf602246ee81c409daab29bdc7-NEmwDYJZoM0d.jpg, createdBy=36c35177966, createdName=156GRoK0535(apple), createdTime=Sat Jul 25 23:32:36 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121134, encodeId=69ca2121134a4, content=请问reviewer assigned需要多久啊?已经等了半个月了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b3b2173627, createdName=1205960dm93(暂无昵称), createdTime=Wed Mar 22 16:16:05 CST 2023, time=2023-03-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2127463, encodeId=9028212e4631c, content=麻烦问下大家都是几天从new submission变成under review的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96762562838, createdName=想想再说, createdTime=Fri Apr 21 11:53:56 CST 2023, time=2023-04-21, status=1, ipAttribution=黑龙江省)]
    2023-10-30 P拾荒者 来自浙江省

    偏重的研究方向:癌症;临床;预后标志物
    经验分享:记录一下过程吧。 10.24提交 10.28 reviewer assigned 10.30 under review 希望有个好结果

    6

    展开6条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2165794, encodeId=4ac12165e9439, content=偏重的研究方向:癌症;临床;预后标志物<br>经验分享:记录一下过程吧。 10.24提交 10.28 reviewer assigned 10.30 under review 希望有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Oct 30 20:47:40 CST 2023, time=2023-10-30, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2102231, encodeId=5f1321022311d, content=偏重的研究方向:乳腺癌;肿瘤<br>经验分享:10.18投稿10.25送外审11.21外审意见回来小修11.22修回11.23接受,效率很快,提出的意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Wed Nov 23 19:49:41 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174151, encodeId=e06f21e41510a, content=审稿速度:1.0<br>经验分享:Nov.3 submission Nov.4 Editor assigned-reviewers assigned Nov.12 日期更新reviewers assigned Nov.14 under review Nov.15 reviewers assigned Nov.30 reviewers assigned Dec.04 reject, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=794c9103199, createdName=ms6000001228150935, createdTime=Sun Dec 10 23:53:27 CST 2023, time=2023-12-10, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2140919, encodeId=690f214091946, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肺癌;基础<br>经验分享:终于结束,就这样!一审审稿比较慢,2个多月,等的有点着急。大修给的截止日期本来是7月份,但因为审稿意见中真正的实验只有一个需要补充,所以修回的比较快,但4个评审意见真是回复到崩溃,太多了。还好四个评审意见都偏积极,我们回复的也够充分,基本都是正面直接回答的。<br>总结:偏临床型杂志,审稿人感觉临床医生居多,所以没有提很多机制性问题,大多问题都跟临床有关。<br><br>14 Feb 2023 submit<br>19 Feb 2023 Editor Invited<br>26 Feb 2023 Under review<br>08 Apr 2023 Reviews Completed<br>12 Apr 2023 Reviews Completed<br>20 Apr 2023 Reviews Completed<br>22 Apr 2023 Major revisions(4个审稿意见,回复意见写了19页)<br>11 May 2023 submit revision R1<br>15 May 2023 Editor Assigned<br>16 May 2023 Major revisions<br>17 May 2023 submit revision R2 又收到了一模一样的大修邮件。沟通后又重新submit <br>18 May 2023 Editor Assigned<br>20 May 2023 Accept<br>26 May 2023 版权协议<br>27 May 2023 proof<br>30 May 2023 online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=631e1736149, createdName=1defbc5bm21(暂无匿称), createdTime=Mon Jun 05 16:54:14 CST 2023, time=2023-06-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2150645, encodeId=eca9215064565, content=偏重的研究方向:肿瘤;癌症;基础<br>经验分享:分享投稿流程 希望可以帮助投稿的小伙伴们 6月7日投稿 6月8日修改参考文献格式重新提交 6月10日分配编辑 6月12日审稿人邀请 审稿人同意 7月21日 小修 审稿人意见很友好 只修改了两处文章标注错误 回答了审稿人两个小问题 7月22日返回修改稿 7月23日接收 审稿时发过两次邮件催稿得到的都是编辑助理回复的文章在审 有消息第一时间通知 编辑处理文章非常快 回复邮件也很快 效率非常高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e178390071, createdName=脸圆环奈, createdTime=Mon Jul 31 16:51:40 CST 2023, time=2023-07-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2145669, encodeId=3f6d2145669f2, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:无理由秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263e1426598, createdName=lichichi1949, createdTime=Fri Jun 30 16:02:30 CST 2023, time=2023-06-30, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2101371, encodeId=6ad721013e159, content=偏重的研究方向:肿瘤<br>经验分享:大佬们under review了一个月昨天又变成Editor Assigned什么意思啊。。这是送了外审没呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Fri Nov 18 18:25:04 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804559, encodeId=f8fc8045597c, content=有没有人一直是reviewers assigned状态啊,这是啥意思啊,而且这个状态还更新了两次日期,这是找不到审稿人是吗?😓, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202406/80984ecf602246ee81c409daab29bdc7-NEmwDYJZoM0d.jpg, createdBy=36c35177966, createdName=156GRoK0535(apple), createdTime=Sat Jul 25 23:32:36 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121134, encodeId=69ca2121134a4, content=请问reviewer assigned需要多久啊?已经等了半个月了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b3b2173627, createdName=1205960dm93(暂无昵称), createdTime=Wed Mar 22 16:16:05 CST 2023, time=2023-03-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2127463, encodeId=9028212e4631c, content=麻烦问下大家都是几天从new submission变成under review的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96762562838, createdName=想想再说, createdTime=Fri Apr 21 11:53:56 CST 2023, time=2023-04-21, status=1, ipAttribution=黑龙江省)]
    2022-11-23 若素9442

    偏重的研究方向:乳腺癌;肿瘤
    经验分享:10.18投稿10.25送外审11.21外审意见回来小修11.22修回11.23接受,效率很快,提出的意见也很中肯

    6

    展开6条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2165794, encodeId=4ac12165e9439, content=偏重的研究方向:癌症;临床;预后标志物<br>经验分享:记录一下过程吧。 10.24提交 10.28 reviewer assigned 10.30 under review 希望有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Oct 30 20:47:40 CST 2023, time=2023-10-30, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2102231, encodeId=5f1321022311d, content=偏重的研究方向:乳腺癌;肿瘤<br>经验分享:10.18投稿10.25送外审11.21外审意见回来小修11.22修回11.23接受,效率很快,提出的意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Wed Nov 23 19:49:41 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174151, encodeId=e06f21e41510a, content=审稿速度:1.0<br>经验分享:Nov.3 submission Nov.4 Editor assigned-reviewers assigned Nov.12 日期更新reviewers assigned Nov.14 under review Nov.15 reviewers assigned Nov.30 reviewers assigned Dec.04 reject, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=794c9103199, createdName=ms6000001228150935, createdTime=Sun Dec 10 23:53:27 CST 2023, time=2023-12-10, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2140919, encodeId=690f214091946, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肺癌;基础<br>经验分享:终于结束,就这样!一审审稿比较慢,2个多月,等的有点着急。大修给的截止日期本来是7月份,但因为审稿意见中真正的实验只有一个需要补充,所以修回的比较快,但4个评审意见真是回复到崩溃,太多了。还好四个评审意见都偏积极,我们回复的也够充分,基本都是正面直接回答的。<br>总结:偏临床型杂志,审稿人感觉临床医生居多,所以没有提很多机制性问题,大多问题都跟临床有关。<br><br>14 Feb 2023 submit<br>19 Feb 2023 Editor Invited<br>26 Feb 2023 Under review<br>08 Apr 2023 Reviews Completed<br>12 Apr 2023 Reviews Completed<br>20 Apr 2023 Reviews Completed<br>22 Apr 2023 Major revisions(4个审稿意见,回复意见写了19页)<br>11 May 2023 submit revision R1<br>15 May 2023 Editor Assigned<br>16 May 2023 Major revisions<br>17 May 2023 submit revision R2 又收到了一模一样的大修邮件。沟通后又重新submit <br>18 May 2023 Editor Assigned<br>20 May 2023 Accept<br>26 May 2023 版权协议<br>27 May 2023 proof<br>30 May 2023 online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=631e1736149, createdName=1defbc5bm21(暂无匿称), createdTime=Mon Jun 05 16:54:14 CST 2023, time=2023-06-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2150645, encodeId=eca9215064565, content=偏重的研究方向:肿瘤;癌症;基础<br>经验分享:分享投稿流程 希望可以帮助投稿的小伙伴们 6月7日投稿 6月8日修改参考文献格式重新提交 6月10日分配编辑 6月12日审稿人邀请 审稿人同意 7月21日 小修 审稿人意见很友好 只修改了两处文章标注错误 回答了审稿人两个小问题 7月22日返回修改稿 7月23日接收 审稿时发过两次邮件催稿得到的都是编辑助理回复的文章在审 有消息第一时间通知 编辑处理文章非常快 回复邮件也很快 效率非常高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e178390071, createdName=脸圆环奈, createdTime=Mon Jul 31 16:51:40 CST 2023, time=2023-07-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2145669, encodeId=3f6d2145669f2, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:无理由秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263e1426598, createdName=lichichi1949, createdTime=Fri Jun 30 16:02:30 CST 2023, time=2023-06-30, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2101371, encodeId=6ad721013e159, content=偏重的研究方向:肿瘤<br>经验分享:大佬们under review了一个月昨天又变成Editor Assigned什么意思啊。。这是送了外审没呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Fri Nov 18 18:25:04 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804559, encodeId=f8fc8045597c, content=有没有人一直是reviewers assigned状态啊,这是啥意思啊,而且这个状态还更新了两次日期,这是找不到审稿人是吗?😓, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202406/80984ecf602246ee81c409daab29bdc7-NEmwDYJZoM0d.jpg, createdBy=36c35177966, createdName=156GRoK0535(apple), createdTime=Sat Jul 25 23:32:36 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121134, encodeId=69ca2121134a4, content=请问reviewer assigned需要多久啊?已经等了半个月了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b3b2173627, createdName=1205960dm93(暂无昵称), createdTime=Wed Mar 22 16:16:05 CST 2023, time=2023-03-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2127463, encodeId=9028212e4631c, content=麻烦问下大家都是几天从new submission变成under review的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96762562838, createdName=想想再说, createdTime=Fri Apr 21 11:53:56 CST 2023, time=2023-04-21, status=1, ipAttribution=黑龙江省)]
    2023-12-10 ms6000001228150935 来自河南省

    审稿速度:1.0
    经验分享:Nov.3 submission Nov.4 Editor assigned-reviewers assigned Nov.12 日期更新reviewers assigned Nov.14 under review Nov.15 reviewers assigned Nov.30 reviewers assigned Dec.04 reject

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2165794, encodeId=4ac12165e9439, content=偏重的研究方向:癌症;临床;预后标志物<br>经验分享:记录一下过程吧。 10.24提交 10.28 reviewer assigned 10.30 under review 希望有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Oct 30 20:47:40 CST 2023, time=2023-10-30, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2102231, encodeId=5f1321022311d, content=偏重的研究方向:乳腺癌;肿瘤<br>经验分享:10.18投稿10.25送外审11.21外审意见回来小修11.22修回11.23接受,效率很快,提出的意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Wed Nov 23 19:49:41 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174151, encodeId=e06f21e41510a, content=审稿速度:1.0<br>经验分享:Nov.3 submission Nov.4 Editor assigned-reviewers assigned Nov.12 日期更新reviewers assigned Nov.14 under review Nov.15 reviewers assigned Nov.30 reviewers assigned Dec.04 reject, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=794c9103199, createdName=ms6000001228150935, createdTime=Sun Dec 10 23:53:27 CST 2023, time=2023-12-10, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2140919, encodeId=690f214091946, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肺癌;基础<br>经验分享:终于结束,就这样!一审审稿比较慢,2个多月,等的有点着急。大修给的截止日期本来是7月份,但因为审稿意见中真正的实验只有一个需要补充,所以修回的比较快,但4个评审意见真是回复到崩溃,太多了。还好四个评审意见都偏积极,我们回复的也够充分,基本都是正面直接回答的。<br>总结:偏临床型杂志,审稿人感觉临床医生居多,所以没有提很多机制性问题,大多问题都跟临床有关。<br><br>14 Feb 2023 submit<br>19 Feb 2023 Editor Invited<br>26 Feb 2023 Under review<br>08 Apr 2023 Reviews Completed<br>12 Apr 2023 Reviews Completed<br>20 Apr 2023 Reviews Completed<br>22 Apr 2023 Major revisions(4个审稿意见,回复意见写了19页)<br>11 May 2023 submit revision R1<br>15 May 2023 Editor Assigned<br>16 May 2023 Major revisions<br>17 May 2023 submit revision R2 又收到了一模一样的大修邮件。沟通后又重新submit <br>18 May 2023 Editor Assigned<br>20 May 2023 Accept<br>26 May 2023 版权协议<br>27 May 2023 proof<br>30 May 2023 online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=631e1736149, createdName=1defbc5bm21(暂无匿称), createdTime=Mon Jun 05 16:54:14 CST 2023, time=2023-06-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2150645, encodeId=eca9215064565, content=偏重的研究方向:肿瘤;癌症;基础<br>经验分享:分享投稿流程 希望可以帮助投稿的小伙伴们 6月7日投稿 6月8日修改参考文献格式重新提交 6月10日分配编辑 6月12日审稿人邀请 审稿人同意 7月21日 小修 审稿人意见很友好 只修改了两处文章标注错误 回答了审稿人两个小问题 7月22日返回修改稿 7月23日接收 审稿时发过两次邮件催稿得到的都是编辑助理回复的文章在审 有消息第一时间通知 编辑处理文章非常快 回复邮件也很快 效率非常高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e178390071, createdName=脸圆环奈, createdTime=Mon Jul 31 16:51:40 CST 2023, time=2023-07-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2145669, encodeId=3f6d2145669f2, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:无理由秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263e1426598, createdName=lichichi1949, createdTime=Fri Jun 30 16:02:30 CST 2023, time=2023-06-30, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2101371, encodeId=6ad721013e159, content=偏重的研究方向:肿瘤<br>经验分享:大佬们under review了一个月昨天又变成Editor Assigned什么意思啊。。这是送了外审没呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Fri Nov 18 18:25:04 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804559, encodeId=f8fc8045597c, content=有没有人一直是reviewers assigned状态啊,这是啥意思啊,而且这个状态还更新了两次日期,这是找不到审稿人是吗?😓, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202406/80984ecf602246ee81c409daab29bdc7-NEmwDYJZoM0d.jpg, createdBy=36c35177966, createdName=156GRoK0535(apple), createdTime=Sat Jul 25 23:32:36 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121134, encodeId=69ca2121134a4, content=请问reviewer assigned需要多久啊?已经等了半个月了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b3b2173627, createdName=1205960dm93(暂无昵称), createdTime=Wed Mar 22 16:16:05 CST 2023, time=2023-03-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2127463, encodeId=9028212e4631c, content=麻烦问下大家都是几天从new submission变成under review的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96762562838, createdName=想想再说, createdTime=Fri Apr 21 11:53:56 CST 2023, time=2023-04-21, status=1, ipAttribution=黑龙江省)]
    2023-06-05 1defbc5bm21(暂无匿称) 来自浙江省

    审稿速度:3.0 | 投稿命中率:95.0
    偏重的研究方向:肺癌;基础
    经验分享:终于结束,就这样!一审审稿比较慢,2个多月,等的有点着急。大修给的截止日期本来是7月份,但因为审稿意见中真正的实验只有一个需要补充,所以修回的比较快,但4个评审意见真是回复到崩溃,太多了。还好四个评审意见都偏积极,我们回复的也够充分,基本都是正面直接回答的。
    总结:偏临床型杂志,审稿人感觉临床医生居多,所以没有提很多机制性问题,大多问题都跟临床有关。

    14 Feb 2023 submit
    19 Feb 2023 Editor Invited
    26 Feb 2023 Under review
    08 Apr 2023 Reviews Completed
    12 Apr 2023 Reviews Completed
    20 Apr 2023 Reviews Completed
    22 Apr 2023 Major revisions(4个审稿意见,回复意见写了19页)
    11 May 2023 submit revision R1
    15 May 2023 Editor Assigned
    16 May 2023 Major revisions
    17 May 2023 submit revision R2 又收到了一模一样的大修邮件。沟通后又重新submit
    18 May 2023 Editor Assigned
    20 May 2023 Accept
    26 May 2023 版权协议
    27 May 2023 proof
    30 May 2023 online

    12

    展开12条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2165794, encodeId=4ac12165e9439, content=偏重的研究方向:癌症;临床;预后标志物<br>经验分享:记录一下过程吧。 10.24提交 10.28 reviewer assigned 10.30 under review 希望有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Oct 30 20:47:40 CST 2023, time=2023-10-30, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2102231, encodeId=5f1321022311d, content=偏重的研究方向:乳腺癌;肿瘤<br>经验分享:10.18投稿10.25送外审11.21外审意见回来小修11.22修回11.23接受,效率很快,提出的意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Wed Nov 23 19:49:41 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174151, encodeId=e06f21e41510a, content=审稿速度:1.0<br>经验分享:Nov.3 submission Nov.4 Editor assigned-reviewers assigned Nov.12 日期更新reviewers assigned Nov.14 under review Nov.15 reviewers assigned Nov.30 reviewers assigned Dec.04 reject, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=794c9103199, createdName=ms6000001228150935, createdTime=Sun Dec 10 23:53:27 CST 2023, time=2023-12-10, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2140919, encodeId=690f214091946, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肺癌;基础<br>经验分享:终于结束,就这样!一审审稿比较慢,2个多月,等的有点着急。大修给的截止日期本来是7月份,但因为审稿意见中真正的实验只有一个需要补充,所以修回的比较快,但4个评审意见真是回复到崩溃,太多了。还好四个评审意见都偏积极,我们回复的也够充分,基本都是正面直接回答的。<br>总结:偏临床型杂志,审稿人感觉临床医生居多,所以没有提很多机制性问题,大多问题都跟临床有关。<br><br>14 Feb 2023 submit<br>19 Feb 2023 Editor Invited<br>26 Feb 2023 Under review<br>08 Apr 2023 Reviews Completed<br>12 Apr 2023 Reviews Completed<br>20 Apr 2023 Reviews Completed<br>22 Apr 2023 Major revisions(4个审稿意见,回复意见写了19页)<br>11 May 2023 submit revision R1<br>15 May 2023 Editor Assigned<br>16 May 2023 Major revisions<br>17 May 2023 submit revision R2 又收到了一模一样的大修邮件。沟通后又重新submit <br>18 May 2023 Editor Assigned<br>20 May 2023 Accept<br>26 May 2023 版权协议<br>27 May 2023 proof<br>30 May 2023 online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=631e1736149, createdName=1defbc5bm21(暂无匿称), createdTime=Mon Jun 05 16:54:14 CST 2023, time=2023-06-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2150645, encodeId=eca9215064565, content=偏重的研究方向:肿瘤;癌症;基础<br>经验分享:分享投稿流程 希望可以帮助投稿的小伙伴们 6月7日投稿 6月8日修改参考文献格式重新提交 6月10日分配编辑 6月12日审稿人邀请 审稿人同意 7月21日 小修 审稿人意见很友好 只修改了两处文章标注错误 回答了审稿人两个小问题 7月22日返回修改稿 7月23日接收 审稿时发过两次邮件催稿得到的都是编辑助理回复的文章在审 有消息第一时间通知 编辑处理文章非常快 回复邮件也很快 效率非常高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e178390071, createdName=脸圆环奈, createdTime=Mon Jul 31 16:51:40 CST 2023, time=2023-07-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2145669, encodeId=3f6d2145669f2, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:无理由秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263e1426598, createdName=lichichi1949, createdTime=Fri Jun 30 16:02:30 CST 2023, time=2023-06-30, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2101371, encodeId=6ad721013e159, content=偏重的研究方向:肿瘤<br>经验分享:大佬们under review了一个月昨天又变成Editor Assigned什么意思啊。。这是送了外审没呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Fri Nov 18 18:25:04 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804559, encodeId=f8fc8045597c, content=有没有人一直是reviewers assigned状态啊,这是啥意思啊,而且这个状态还更新了两次日期,这是找不到审稿人是吗?😓, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202406/80984ecf602246ee81c409daab29bdc7-NEmwDYJZoM0d.jpg, createdBy=36c35177966, createdName=156GRoK0535(apple), createdTime=Sat Jul 25 23:32:36 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121134, encodeId=69ca2121134a4, content=请问reviewer assigned需要多久啊?已经等了半个月了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b3b2173627, createdName=1205960dm93(暂无昵称), createdTime=Wed Mar 22 16:16:05 CST 2023, time=2023-03-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2127463, encodeId=9028212e4631c, content=麻烦问下大家都是几天从new submission变成under review的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96762562838, createdName=想想再说, createdTime=Fri Apr 21 11:53:56 CST 2023, time=2023-04-21, status=1, ipAttribution=黑龙江省)]
    2023-07-31 脸圆环奈 来自湖北省

    偏重的研究方向:肿瘤;癌症;基础
    经验分享:分享投稿流程 希望可以帮助投稿的小伙伴们 6月7日投稿 6月8日修改参考文献格式重新提交 6月10日分配编辑 6月12日审稿人邀请 审稿人同意 7月21日 小修 审稿人意见很友好 只修改了两处文章标注错误 回答了审稿人两个小问题 7月22日返回修改稿 7月23日接收 审稿时发过两次邮件催稿得到的都是编辑助理回复的文章在审 有消息第一时间通知 编辑处理文章非常快 回复邮件也很快 效率非常高的杂志

    10

    展开10条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2165794, encodeId=4ac12165e9439, content=偏重的研究方向:癌症;临床;预后标志物<br>经验分享:记录一下过程吧。 10.24提交 10.28 reviewer assigned 10.30 under review 希望有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Oct 30 20:47:40 CST 2023, time=2023-10-30, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2102231, encodeId=5f1321022311d, content=偏重的研究方向:乳腺癌;肿瘤<br>经验分享:10.18投稿10.25送外审11.21外审意见回来小修11.22修回11.23接受,效率很快,提出的意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Wed Nov 23 19:49:41 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174151, encodeId=e06f21e41510a, content=审稿速度:1.0<br>经验分享:Nov.3 submission Nov.4 Editor assigned-reviewers assigned Nov.12 日期更新reviewers assigned Nov.14 under review Nov.15 reviewers assigned Nov.30 reviewers assigned Dec.04 reject, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=794c9103199, createdName=ms6000001228150935, createdTime=Sun Dec 10 23:53:27 CST 2023, time=2023-12-10, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2140919, encodeId=690f214091946, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肺癌;基础<br>经验分享:终于结束,就这样!一审审稿比较慢,2个多月,等的有点着急。大修给的截止日期本来是7月份,但因为审稿意见中真正的实验只有一个需要补充,所以修回的比较快,但4个评审意见真是回复到崩溃,太多了。还好四个评审意见都偏积极,我们回复的也够充分,基本都是正面直接回答的。<br>总结:偏临床型杂志,审稿人感觉临床医生居多,所以没有提很多机制性问题,大多问题都跟临床有关。<br><br>14 Feb 2023 submit<br>19 Feb 2023 Editor Invited<br>26 Feb 2023 Under review<br>08 Apr 2023 Reviews Completed<br>12 Apr 2023 Reviews Completed<br>20 Apr 2023 Reviews Completed<br>22 Apr 2023 Major revisions(4个审稿意见,回复意见写了19页)<br>11 May 2023 submit revision R1<br>15 May 2023 Editor Assigned<br>16 May 2023 Major revisions<br>17 May 2023 submit revision R2 又收到了一模一样的大修邮件。沟通后又重新submit <br>18 May 2023 Editor Assigned<br>20 May 2023 Accept<br>26 May 2023 版权协议<br>27 May 2023 proof<br>30 May 2023 online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=631e1736149, createdName=1defbc5bm21(暂无匿称), createdTime=Mon Jun 05 16:54:14 CST 2023, time=2023-06-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2150645, encodeId=eca9215064565, content=偏重的研究方向:肿瘤;癌症;基础<br>经验分享:分享投稿流程 希望可以帮助投稿的小伙伴们 6月7日投稿 6月8日修改参考文献格式重新提交 6月10日分配编辑 6月12日审稿人邀请 审稿人同意 7月21日 小修 审稿人意见很友好 只修改了两处文章标注错误 回答了审稿人两个小问题 7月22日返回修改稿 7月23日接收 审稿时发过两次邮件催稿得到的都是编辑助理回复的文章在审 有消息第一时间通知 编辑处理文章非常快 回复邮件也很快 效率非常高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e178390071, createdName=脸圆环奈, createdTime=Mon Jul 31 16:51:40 CST 2023, time=2023-07-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2145669, encodeId=3f6d2145669f2, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:无理由秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263e1426598, createdName=lichichi1949, createdTime=Fri Jun 30 16:02:30 CST 2023, time=2023-06-30, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2101371, encodeId=6ad721013e159, content=偏重的研究方向:肿瘤<br>经验分享:大佬们under review了一个月昨天又变成Editor Assigned什么意思啊。。这是送了外审没呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Fri Nov 18 18:25:04 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804559, encodeId=f8fc8045597c, content=有没有人一直是reviewers assigned状态啊,这是啥意思啊,而且这个状态还更新了两次日期,这是找不到审稿人是吗?😓, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202406/80984ecf602246ee81c409daab29bdc7-NEmwDYJZoM0d.jpg, createdBy=36c35177966, createdName=156GRoK0535(apple), createdTime=Sat Jul 25 23:32:36 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121134, encodeId=69ca2121134a4, content=请问reviewer assigned需要多久啊?已经等了半个月了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b3b2173627, createdName=1205960dm93(暂无昵称), createdTime=Wed Mar 22 16:16:05 CST 2023, time=2023-03-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2127463, encodeId=9028212e4631c, content=麻烦问下大家都是几天从new submission变成under review的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96762562838, createdName=想想再说, createdTime=Fri Apr 21 11:53:56 CST 2023, time=2023-04-21, status=1, ipAttribution=黑龙江省)]
    2023-06-30 lichichi1949 来自四川省

    审稿速度:1.0 | 投稿命中率:50.0
    经验分享:无理由秒拒

    3

    展开3条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2165794, encodeId=4ac12165e9439, content=偏重的研究方向:癌症;临床;预后标志物<br>经验分享:记录一下过程吧。 10.24提交 10.28 reviewer assigned 10.30 under review 希望有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Oct 30 20:47:40 CST 2023, time=2023-10-30, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2102231, encodeId=5f1321022311d, content=偏重的研究方向:乳腺癌;肿瘤<br>经验分享:10.18投稿10.25送外审11.21外审意见回来小修11.22修回11.23接受,效率很快,提出的意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Wed Nov 23 19:49:41 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174151, encodeId=e06f21e41510a, content=审稿速度:1.0<br>经验分享:Nov.3 submission Nov.4 Editor assigned-reviewers assigned Nov.12 日期更新reviewers assigned Nov.14 under review Nov.15 reviewers assigned Nov.30 reviewers assigned Dec.04 reject, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=794c9103199, createdName=ms6000001228150935, createdTime=Sun Dec 10 23:53:27 CST 2023, time=2023-12-10, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2140919, encodeId=690f214091946, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肺癌;基础<br>经验分享:终于结束,就这样!一审审稿比较慢,2个多月,等的有点着急。大修给的截止日期本来是7月份,但因为审稿意见中真正的实验只有一个需要补充,所以修回的比较快,但4个评审意见真是回复到崩溃,太多了。还好四个评审意见都偏积极,我们回复的也够充分,基本都是正面直接回答的。<br>总结:偏临床型杂志,审稿人感觉临床医生居多,所以没有提很多机制性问题,大多问题都跟临床有关。<br><br>14 Feb 2023 submit<br>19 Feb 2023 Editor Invited<br>26 Feb 2023 Under review<br>08 Apr 2023 Reviews Completed<br>12 Apr 2023 Reviews Completed<br>20 Apr 2023 Reviews Completed<br>22 Apr 2023 Major revisions(4个审稿意见,回复意见写了19页)<br>11 May 2023 submit revision R1<br>15 May 2023 Editor Assigned<br>16 May 2023 Major revisions<br>17 May 2023 submit revision R2 又收到了一模一样的大修邮件。沟通后又重新submit <br>18 May 2023 Editor Assigned<br>20 May 2023 Accept<br>26 May 2023 版权协议<br>27 May 2023 proof<br>30 May 2023 online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=631e1736149, createdName=1defbc5bm21(暂无匿称), createdTime=Mon Jun 05 16:54:14 CST 2023, time=2023-06-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2150645, encodeId=eca9215064565, content=偏重的研究方向:肿瘤;癌症;基础<br>经验分享:分享投稿流程 希望可以帮助投稿的小伙伴们 6月7日投稿 6月8日修改参考文献格式重新提交 6月10日分配编辑 6月12日审稿人邀请 审稿人同意 7月21日 小修 审稿人意见很友好 只修改了两处文章标注错误 回答了审稿人两个小问题 7月22日返回修改稿 7月23日接收 审稿时发过两次邮件催稿得到的都是编辑助理回复的文章在审 有消息第一时间通知 编辑处理文章非常快 回复邮件也很快 效率非常高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e178390071, createdName=脸圆环奈, createdTime=Mon Jul 31 16:51:40 CST 2023, time=2023-07-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2145669, encodeId=3f6d2145669f2, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:无理由秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263e1426598, createdName=lichichi1949, createdTime=Fri Jun 30 16:02:30 CST 2023, time=2023-06-30, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2101371, encodeId=6ad721013e159, content=偏重的研究方向:肿瘤<br>经验分享:大佬们under review了一个月昨天又变成Editor Assigned什么意思啊。。这是送了外审没呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Fri Nov 18 18:25:04 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804559, encodeId=f8fc8045597c, content=有没有人一直是reviewers assigned状态啊,这是啥意思啊,而且这个状态还更新了两次日期,这是找不到审稿人是吗?😓, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202406/80984ecf602246ee81c409daab29bdc7-NEmwDYJZoM0d.jpg, createdBy=36c35177966, createdName=156GRoK0535(apple), createdTime=Sat Jul 25 23:32:36 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121134, encodeId=69ca2121134a4, content=请问reviewer assigned需要多久啊?已经等了半个月了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b3b2173627, createdName=1205960dm93(暂无昵称), createdTime=Wed Mar 22 16:16:05 CST 2023, time=2023-03-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2127463, encodeId=9028212e4631c, content=麻烦问下大家都是几天从new submission变成under review的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96762562838, createdName=想想再说, createdTime=Fri Apr 21 11:53:56 CST 2023, time=2023-04-21, status=1, ipAttribution=黑龙江省)]
    2022-11-18 若素9442

    偏重的研究方向:肿瘤
    经验分享:大佬们under review了一个月昨天又变成Editor Assigned什么意思啊。。这是送了外审没呀

    9

    展开9条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2165794, encodeId=4ac12165e9439, content=偏重的研究方向:癌症;临床;预后标志物<br>经验分享:记录一下过程吧。 10.24提交 10.28 reviewer assigned 10.30 under review 希望有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Oct 30 20:47:40 CST 2023, time=2023-10-30, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2102231, encodeId=5f1321022311d, content=偏重的研究方向:乳腺癌;肿瘤<br>经验分享:10.18投稿10.25送外审11.21外审意见回来小修11.22修回11.23接受,效率很快,提出的意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Wed Nov 23 19:49:41 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174151, encodeId=e06f21e41510a, content=审稿速度:1.0<br>经验分享:Nov.3 submission Nov.4 Editor assigned-reviewers assigned Nov.12 日期更新reviewers assigned Nov.14 under review Nov.15 reviewers assigned Nov.30 reviewers assigned Dec.04 reject, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=794c9103199, createdName=ms6000001228150935, createdTime=Sun Dec 10 23:53:27 CST 2023, time=2023-12-10, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2140919, encodeId=690f214091946, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肺癌;基础<br>经验分享:终于结束,就这样!一审审稿比较慢,2个多月,等的有点着急。大修给的截止日期本来是7月份,但因为审稿意见中真正的实验只有一个需要补充,所以修回的比较快,但4个评审意见真是回复到崩溃,太多了。还好四个评审意见都偏积极,我们回复的也够充分,基本都是正面直接回答的。<br>总结:偏临床型杂志,审稿人感觉临床医生居多,所以没有提很多机制性问题,大多问题都跟临床有关。<br><br>14 Feb 2023 submit<br>19 Feb 2023 Editor Invited<br>26 Feb 2023 Under review<br>08 Apr 2023 Reviews Completed<br>12 Apr 2023 Reviews Completed<br>20 Apr 2023 Reviews Completed<br>22 Apr 2023 Major revisions(4个审稿意见,回复意见写了19页)<br>11 May 2023 submit revision R1<br>15 May 2023 Editor Assigned<br>16 May 2023 Major revisions<br>17 May 2023 submit revision R2 又收到了一模一样的大修邮件。沟通后又重新submit <br>18 May 2023 Editor Assigned<br>20 May 2023 Accept<br>26 May 2023 版权协议<br>27 May 2023 proof<br>30 May 2023 online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=631e1736149, createdName=1defbc5bm21(暂无匿称), createdTime=Mon Jun 05 16:54:14 CST 2023, time=2023-06-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2150645, encodeId=eca9215064565, content=偏重的研究方向:肿瘤;癌症;基础<br>经验分享:分享投稿流程 希望可以帮助投稿的小伙伴们 6月7日投稿 6月8日修改参考文献格式重新提交 6月10日分配编辑 6月12日审稿人邀请 审稿人同意 7月21日 小修 审稿人意见很友好 只修改了两处文章标注错误 回答了审稿人两个小问题 7月22日返回修改稿 7月23日接收 审稿时发过两次邮件催稿得到的都是编辑助理回复的文章在审 有消息第一时间通知 编辑处理文章非常快 回复邮件也很快 效率非常高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e178390071, createdName=脸圆环奈, createdTime=Mon Jul 31 16:51:40 CST 2023, time=2023-07-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2145669, encodeId=3f6d2145669f2, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:无理由秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263e1426598, createdName=lichichi1949, createdTime=Fri Jun 30 16:02:30 CST 2023, time=2023-06-30, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2101371, encodeId=6ad721013e159, content=偏重的研究方向:肿瘤<br>经验分享:大佬们under review了一个月昨天又变成Editor Assigned什么意思啊。。这是送了外审没呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Fri Nov 18 18:25:04 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804559, encodeId=f8fc8045597c, content=有没有人一直是reviewers assigned状态啊,这是啥意思啊,而且这个状态还更新了两次日期,这是找不到审稿人是吗?😓, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202406/80984ecf602246ee81c409daab29bdc7-NEmwDYJZoM0d.jpg, createdBy=36c35177966, createdName=156GRoK0535(apple), createdTime=Sat Jul 25 23:32:36 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121134, encodeId=69ca2121134a4, content=请问reviewer assigned需要多久啊?已经等了半个月了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b3b2173627, createdName=1205960dm93(暂无昵称), createdTime=Wed Mar 22 16:16:05 CST 2023, time=2023-03-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2127463, encodeId=9028212e4631c, content=麻烦问下大家都是几天从new submission变成under review的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96762562838, createdName=想想再说, createdTime=Fri Apr 21 11:53:56 CST 2023, time=2023-04-21, status=1, ipAttribution=黑龙江省)]
    2020-07-25 156GRoK0535(apple)

    有没有人一直是reviewers assigned状态啊,这是啥意思啊,而且这个状态还更新了两次日期,这是找不到审稿人是吗?😓

    5

    展开5条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2165794, encodeId=4ac12165e9439, content=偏重的研究方向:癌症;临床;预后标志物<br>经验分享:记录一下过程吧。 10.24提交 10.28 reviewer assigned 10.30 under review 希望有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Oct 30 20:47:40 CST 2023, time=2023-10-30, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2102231, encodeId=5f1321022311d, content=偏重的研究方向:乳腺癌;肿瘤<br>经验分享:10.18投稿10.25送外审11.21外审意见回来小修11.22修回11.23接受,效率很快,提出的意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Wed Nov 23 19:49:41 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174151, encodeId=e06f21e41510a, content=审稿速度:1.0<br>经验分享:Nov.3 submission Nov.4 Editor assigned-reviewers assigned Nov.12 日期更新reviewers assigned Nov.14 under review Nov.15 reviewers assigned Nov.30 reviewers assigned Dec.04 reject, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=794c9103199, createdName=ms6000001228150935, createdTime=Sun Dec 10 23:53:27 CST 2023, time=2023-12-10, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2140919, encodeId=690f214091946, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肺癌;基础<br>经验分享:终于结束,就这样!一审审稿比较慢,2个多月,等的有点着急。大修给的截止日期本来是7月份,但因为审稿意见中真正的实验只有一个需要补充,所以修回的比较快,但4个评审意见真是回复到崩溃,太多了。还好四个评审意见都偏积极,我们回复的也够充分,基本都是正面直接回答的。<br>总结:偏临床型杂志,审稿人感觉临床医生居多,所以没有提很多机制性问题,大多问题都跟临床有关。<br><br>14 Feb 2023 submit<br>19 Feb 2023 Editor Invited<br>26 Feb 2023 Under review<br>08 Apr 2023 Reviews Completed<br>12 Apr 2023 Reviews Completed<br>20 Apr 2023 Reviews Completed<br>22 Apr 2023 Major revisions(4个审稿意见,回复意见写了19页)<br>11 May 2023 submit revision R1<br>15 May 2023 Editor Assigned<br>16 May 2023 Major revisions<br>17 May 2023 submit revision R2 又收到了一模一样的大修邮件。沟通后又重新submit <br>18 May 2023 Editor Assigned<br>20 May 2023 Accept<br>26 May 2023 版权协议<br>27 May 2023 proof<br>30 May 2023 online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=631e1736149, createdName=1defbc5bm21(暂无匿称), createdTime=Mon Jun 05 16:54:14 CST 2023, time=2023-06-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2150645, encodeId=eca9215064565, content=偏重的研究方向:肿瘤;癌症;基础<br>经验分享:分享投稿流程 希望可以帮助投稿的小伙伴们 6月7日投稿 6月8日修改参考文献格式重新提交 6月10日分配编辑 6月12日审稿人邀请 审稿人同意 7月21日 小修 审稿人意见很友好 只修改了两处文章标注错误 回答了审稿人两个小问题 7月22日返回修改稿 7月23日接收 审稿时发过两次邮件催稿得到的都是编辑助理回复的文章在审 有消息第一时间通知 编辑处理文章非常快 回复邮件也很快 效率非常高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e178390071, createdName=脸圆环奈, createdTime=Mon Jul 31 16:51:40 CST 2023, time=2023-07-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2145669, encodeId=3f6d2145669f2, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:无理由秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263e1426598, createdName=lichichi1949, createdTime=Fri Jun 30 16:02:30 CST 2023, time=2023-06-30, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2101371, encodeId=6ad721013e159, content=偏重的研究方向:肿瘤<br>经验分享:大佬们under review了一个月昨天又变成Editor Assigned什么意思啊。。这是送了外审没呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Fri Nov 18 18:25:04 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804559, encodeId=f8fc8045597c, content=有没有人一直是reviewers assigned状态啊,这是啥意思啊,而且这个状态还更新了两次日期,这是找不到审稿人是吗?😓, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202406/80984ecf602246ee81c409daab29bdc7-NEmwDYJZoM0d.jpg, createdBy=36c35177966, createdName=156GRoK0535(apple), createdTime=Sat Jul 25 23:32:36 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121134, encodeId=69ca2121134a4, content=请问reviewer assigned需要多久啊?已经等了半个月了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b3b2173627, createdName=1205960dm93(暂无昵称), createdTime=Wed Mar 22 16:16:05 CST 2023, time=2023-03-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2127463, encodeId=9028212e4631c, content=麻烦问下大家都是几天从new submission变成under review的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96762562838, createdName=想想再说, createdTime=Fri Apr 21 11:53:56 CST 2023, time=2023-04-21, status=1, ipAttribution=黑龙江省)]
    2023-03-22 1205960dm93(暂无昵称) 来自上海

    请问reviewer assigned需要多久啊?已经等了半个月了

    3

    展开3条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2165794, encodeId=4ac12165e9439, content=偏重的研究方向:癌症;临床;预后标志物<br>经验分享:记录一下过程吧。 10.24提交 10.28 reviewer assigned 10.30 under review 希望有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Oct 30 20:47:40 CST 2023, time=2023-10-30, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2102231, encodeId=5f1321022311d, content=偏重的研究方向:乳腺癌;肿瘤<br>经验分享:10.18投稿10.25送外审11.21外审意见回来小修11.22修回11.23接受,效率很快,提出的意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Wed Nov 23 19:49:41 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174151, encodeId=e06f21e41510a, content=审稿速度:1.0<br>经验分享:Nov.3 submission Nov.4 Editor assigned-reviewers assigned Nov.12 日期更新reviewers assigned Nov.14 under review Nov.15 reviewers assigned Nov.30 reviewers assigned Dec.04 reject, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=794c9103199, createdName=ms6000001228150935, createdTime=Sun Dec 10 23:53:27 CST 2023, time=2023-12-10, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2140919, encodeId=690f214091946, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肺癌;基础<br>经验分享:终于结束,就这样!一审审稿比较慢,2个多月,等的有点着急。大修给的截止日期本来是7月份,但因为审稿意见中真正的实验只有一个需要补充,所以修回的比较快,但4个评审意见真是回复到崩溃,太多了。还好四个评审意见都偏积极,我们回复的也够充分,基本都是正面直接回答的。<br>总结:偏临床型杂志,审稿人感觉临床医生居多,所以没有提很多机制性问题,大多问题都跟临床有关。<br><br>14 Feb 2023 submit<br>19 Feb 2023 Editor Invited<br>26 Feb 2023 Under review<br>08 Apr 2023 Reviews Completed<br>12 Apr 2023 Reviews Completed<br>20 Apr 2023 Reviews Completed<br>22 Apr 2023 Major revisions(4个审稿意见,回复意见写了19页)<br>11 May 2023 submit revision R1<br>15 May 2023 Editor Assigned<br>16 May 2023 Major revisions<br>17 May 2023 submit revision R2 又收到了一模一样的大修邮件。沟通后又重新submit <br>18 May 2023 Editor Assigned<br>20 May 2023 Accept<br>26 May 2023 版权协议<br>27 May 2023 proof<br>30 May 2023 online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=631e1736149, createdName=1defbc5bm21(暂无匿称), createdTime=Mon Jun 05 16:54:14 CST 2023, time=2023-06-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2150645, encodeId=eca9215064565, content=偏重的研究方向:肿瘤;癌症;基础<br>经验分享:分享投稿流程 希望可以帮助投稿的小伙伴们 6月7日投稿 6月8日修改参考文献格式重新提交 6月10日分配编辑 6月12日审稿人邀请 审稿人同意 7月21日 小修 审稿人意见很友好 只修改了两处文章标注错误 回答了审稿人两个小问题 7月22日返回修改稿 7月23日接收 审稿时发过两次邮件催稿得到的都是编辑助理回复的文章在审 有消息第一时间通知 编辑处理文章非常快 回复邮件也很快 效率非常高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e178390071, createdName=脸圆环奈, createdTime=Mon Jul 31 16:51:40 CST 2023, time=2023-07-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2145669, encodeId=3f6d2145669f2, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:无理由秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263e1426598, createdName=lichichi1949, createdTime=Fri Jun 30 16:02:30 CST 2023, time=2023-06-30, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2101371, encodeId=6ad721013e159, content=偏重的研究方向:肿瘤<br>经验分享:大佬们under review了一个月昨天又变成Editor Assigned什么意思啊。。这是送了外审没呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Fri Nov 18 18:25:04 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804559, encodeId=f8fc8045597c, content=有没有人一直是reviewers assigned状态啊,这是啥意思啊,而且这个状态还更新了两次日期,这是找不到审稿人是吗?😓, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202406/80984ecf602246ee81c409daab29bdc7-NEmwDYJZoM0d.jpg, createdBy=36c35177966, createdName=156GRoK0535(apple), createdTime=Sat Jul 25 23:32:36 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121134, encodeId=69ca2121134a4, content=请问reviewer assigned需要多久啊?已经等了半个月了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b3b2173627, createdName=1205960dm93(暂无昵称), createdTime=Wed Mar 22 16:16:05 CST 2023, time=2023-03-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2127463, encodeId=9028212e4631c, content=麻烦问下大家都是几天从new submission变成under review的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96762562838, createdName=想想再说, createdTime=Fri Apr 21 11:53:56 CST 2023, time=2023-04-21, status=1, ipAttribution=黑龙江省)]
    2023-04-21 想想再说 来自黑龙江省

    麻烦问下大家都是几天从new submission变成under review的?

    1

    展开1条回复
共190条页码: 1/19页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分

Baidu
Baidu
map
Baidu
map
Baidu
map